Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers-Reference-Cited by-同舟云学术

Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers

Published:2006-05 Issue:5 Volume:50 Page:1881-1883
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sansone-Parsons Angela¹,Krishna Gopal¹,Calzetta Angela¹,Wexler David¹,Kantesaria Bhavna¹,Rosenberg Mitchell A.²,Saltzman Marc A.²

Affiliation:

1. Schering-Plough Research Institute, Kenilworth, New Jersey

2. Parkway Research Center, Inc., North Miami, Florida

Abstract

ABSTRACT We conducted a randomized, crossover study in healthy adults to examine the effects of a nutritional supplement (Boost Plus) on posaconazole pharmacokinetics. In this study, coadministration of posaconazole with Boost Plus increased the maximum concentration of posaconazole in serum and area under the concentration-time curve from 0 to 72 h values 3.4- and 2.6-fold, respectively, compared to those for the fasted state.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.50.5.1881-1883.2006

Reference12 articles.

1. Anstead, G. M., G. Corcoran, J. Lewis, D. Berg, and J. R. Graybill. 2005. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis.40:1770-1776.

2. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol.57:218-222.

3. Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men

4. Courtney, R., A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin, and S. Swan. 2005. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol.45:185-192.

5. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother.51:45-52.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Use of a Kinetic pH Calculation to Correct the ACAT Model with a Single Stomach Compartment Setting: Impact of Stomach Setting on Food Effect Prediction for Basic Compounds;Journal of Pharmaceutical Sciences;2023-07

2. A Review of Population Pharmacokinetic Models of Posaconazole;Drug Design, Development and Therapy;2022-10

3. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections;Advances in Therapy;2022-02-15

4. The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles;Pharmaceutics;2021-11-19

5. Pharmacists role in addressing health disparities—Part 1: Social determinants of health and their intersectionality with medication use, health care utilization, and health outcomes;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2021-11-17